Cargando…
Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome
BACKGROUND: Contralateral delayed endolymphatic hydrops (CDEH) is a clinical entity characterized by fluctuating low frequency hearing loss and/or vertigo, mimicking Ménière’s disease (MD), that manifests after the appearance of severe non-hydropic hearing loss (NHHL) at the other ear. OBJECTIVES: t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese PLA General Hospital
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438629/ https://www.ncbi.nlm.nih.gov/pubmed/34548865 http://dx.doi.org/10.1016/j.joto.2021.02.003 |
_version_ | 1783752384419201024 |
---|---|
author | Albera, Andrea Canale, Andrea Boldreghini, Marco Lucisano, Sergio Riva, Giuseppe Albera, Roberto |
author_facet | Albera, Andrea Canale, Andrea Boldreghini, Marco Lucisano, Sergio Riva, Giuseppe Albera, Roberto |
author_sort | Albera, Andrea |
collection | PubMed |
description | BACKGROUND: Contralateral delayed endolymphatic hydrops (CDEH) is a clinical entity characterized by fluctuating low frequency hearing loss and/or vertigo, mimicking Ménière’s disease (MD), that manifests after the appearance of severe non-hydropic hearing loss (NHHL) at the other ear. OBJECTIVES: to describe the clinical features and the course of 57 patients affected by CDEH. METHOD: this is a retrospective study; 57 patients affected by CDEH, out of 1065 patients seen in the same period and affected by MD, were subjected to otoscopy, PTA threshold evaluation, impedance testing, ABR, research of positioning nystagmus, vestibular function evaluated by means of bithermal caloric test under video-oculographic, and MRI with gadolinium. RESULTS: the CDEH was definite in 24 cases (42%), probable in 2 (4%) and possible in 31 (54%). The mean PTA threshold at the hydropic ear was 41 dB. At the last follow-up, 40 patients (70%) did not report vertigo or fluctuating hearing loss. Among the 17 patients who still reported symptomatology, 11 (64%) were affected by fluctuating hearing loss alone, 4 (23%) reported a subjective worsening of hearing loss and 2 (12%) an acute vertigo crisis. CONCLUSIONS: contralateral delayed endolymphatic hydrops is a relatively rare form of Ménière disease that manifests more frequently as a definite form or with fluctuating low-frequency hearing loss. The prognosis at a long term follow-up is relatively good in terms of vertigo resolution. Contralateral delayed endolymphatic hydrops rarely determines a severe hearing loss in the better ear. |
format | Online Article Text |
id | pubmed-8438629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Chinese PLA General Hospital |
record_format | MEDLINE/PubMed |
spelling | pubmed-84386292021-09-20 Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome Albera, Andrea Canale, Andrea Boldreghini, Marco Lucisano, Sergio Riva, Giuseppe Albera, Roberto J Otol Research Article BACKGROUND: Contralateral delayed endolymphatic hydrops (CDEH) is a clinical entity characterized by fluctuating low frequency hearing loss and/or vertigo, mimicking Ménière’s disease (MD), that manifests after the appearance of severe non-hydropic hearing loss (NHHL) at the other ear. OBJECTIVES: to describe the clinical features and the course of 57 patients affected by CDEH. METHOD: this is a retrospective study; 57 patients affected by CDEH, out of 1065 patients seen in the same period and affected by MD, were subjected to otoscopy, PTA threshold evaluation, impedance testing, ABR, research of positioning nystagmus, vestibular function evaluated by means of bithermal caloric test under video-oculographic, and MRI with gadolinium. RESULTS: the CDEH was definite in 24 cases (42%), probable in 2 (4%) and possible in 31 (54%). The mean PTA threshold at the hydropic ear was 41 dB. At the last follow-up, 40 patients (70%) did not report vertigo or fluctuating hearing loss. Among the 17 patients who still reported symptomatology, 11 (64%) were affected by fluctuating hearing loss alone, 4 (23%) reported a subjective worsening of hearing loss and 2 (12%) an acute vertigo crisis. CONCLUSIONS: contralateral delayed endolymphatic hydrops is a relatively rare form of Ménière disease that manifests more frequently as a definite form or with fluctuating low-frequency hearing loss. The prognosis at a long term follow-up is relatively good in terms of vertigo resolution. Contralateral delayed endolymphatic hydrops rarely determines a severe hearing loss in the better ear. Chinese PLA General Hospital 2021-10 2021-02-26 /pmc/articles/PMC8438629/ /pubmed/34548865 http://dx.doi.org/10.1016/j.joto.2021.02.003 Text en © 2021 PLA General Hospital Department of Otolaryngology Head and Neck Surgery. Production and hosting by Elsevier (Singapore) Pte Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Albera, Andrea Canale, Andrea Boldreghini, Marco Lucisano, Sergio Riva, Giuseppe Albera, Roberto Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome |
title | Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome |
title_full | Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome |
title_fullStr | Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome |
title_full_unstemmed | Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome |
title_short | Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome |
title_sort | contralateral delayed endolymphatic hydrops: clinical features and long term outcome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438629/ https://www.ncbi.nlm.nih.gov/pubmed/34548865 http://dx.doi.org/10.1016/j.joto.2021.02.003 |
work_keys_str_mv | AT alberaandrea contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome AT canaleandrea contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome AT boldreghinimarco contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome AT lucisanosergio contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome AT rivagiuseppe contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome AT alberaroberto contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome |